The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Bisphosphonates Reduce Bone Toughness Over Time

Bisphosphonates Reduce Bone Toughness Over Time

August 11, 2020 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review.

You Might Also Like
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • When Is It Appropriate to Discontinue Bisphosphonates?
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

“Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B. Burr, PhD, of Indiana University School of Medicine, Indianapolis, tells Reuters Health by email. “Therefore, it is best if a patient taking bisphosphonates for five years is checked by a doctor to determine whether they need to continue or should go on a ‘drug holiday.'”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Bisphosphonates have been around for 50 years, but 25 years after their approval for use in humans, their mechanical effects on bone are still not fully understood. In the new report in Bone, Dr. Burr reviews what is known about this topic.1

Treatment with bisphosphonates for one to three years increases bone mineral density (BMD), strength and stiffness of lumbar vertebrae in compression but has little effect on the properties of diaphyseal bone.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Energy required to fracture vertebrae and cortical bone of the ribs declines with treatment duration, which suggests that tissue properties might become impaired.

Over the long term, true fracture mechanics tests suggest cortical bone toughness declines by about 20% or more, despite increased hardness and modulus with bisphosphonates treatment.

More potent bisphosphonates or higher doses of a given bisphosphonate may improve bone structural properties, but they do not have a significantly greater effect on material properties, compared with less potent or lower doses of bisphosphonates.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Studies in dogs suggest that longer duration of treatment with alendronate is associated with greater loss of toughness. But computational models differ about whether elastic modulus, failure stress and hardness begin to decline after a prolonged period of treatment or increase for several years and then plateau.

“Tests of cyclic loading of bone—which is what we do in ‘real life’—shows that bone treated with BPs can fracture with fewer numbers of cycles [a cycle being, for instance, taking a step],” Dr. Burr explains. “So, the bottom line is: Bisphosphonates can reduce risk of fracture by preventing bone loss and maintain bone mass and bone mineral density … However, long-term treatment can lead to impaired properties of the tissue that can have negative side effects in some people.”

“Because duration of treatment is important to mechanical properties, patients need to be monitored after 3–5 years of bisphosphonates treatment,” he says. “Some may not need to be on bisphosphonates more than 3–5 years consecutively. Another implication is that most patients should not be administered bisphosphonates preventatively when they are younger, because over a long duration of treatment this can impair properties of the bone tissue.”

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: bisphosphonates, bone, bone mineral density (BMD), Fractures, Osteoporosis, osteoporosis treatments

You Might Also Like:
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • When Is It Appropriate to Discontinue Bisphosphonates?
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA
  • Alterations in the Microbiome Are Associated with Changes in Bone Quality

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)